Find comprehensive information on Papillary Thyroid Carcinoma, including clinical documentation, medical coding (ICD-10 C73), diagnostic criteria, treatment options, and pathology reports. Learn about the latest research, prognosis, and support resources for patients diagnosed with PTC. This resource offers valuable insights for healthcare professionals, including physicians, nurses, and medical coders, seeking accurate and up-to-date information on Papillary Thyroid Cancer.
Also known as
Malignant neoplasm of thyroid gland
Cancers originating in the thyroid gland.
Malignant neoplasm of thyroid, unspecified
Thyroid cancer without further specification.
Malignant neoplasm of thyroid isthmus
Cancer located in the narrowest part of the thyroid.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the papillary thyroid carcinoma follicular variant?
Incorrect code assignment due to variant histology like follicular, tall cell, or columnar, impacting severity and treatment.
Inadequate documentation of tumor size for accurate T staging, affecting risk stratification and coding.
Missing or unclear documentation of lymph node involvement (N staging), leading to inaccurate coding and treatment planning.
Q: What are the most reliable diagnostic markers for differentiating benign thyroid nodules from papillary thyroid carcinoma in fine-needle aspiration biopsy (FNAB) results?
A: While FNAB is the gold standard for evaluating thyroid nodules, distinguishing benign from malignant can be challenging. Specific cytological features highly suggestive of papillary thyroid carcinoma include nuclear features such as nuclear grooves, intranuclear inclusions (pseudoinclusions), and powdery chromatin. Other suspicious features include psammoma bodies and Hürthle cell change. However, overlapping features can exist. When FNAB results are indeterminate (e.g., atypia of undetermined significance/follicular lesion of undetermined significance or follicular neoplasm/suspicious for a follicular neoplasm), molecular testing (e.g., gene expression classifier or mutation analysis) may be considered to further risk-stratify the nodule and guide management. Explore how integrating molecular markers with cytopathology can improve diagnostic accuracy for challenging cases.
Q: How do I approach the management of papillary thyroid microcarcinoma (PTMC) in a patient with low-risk features and no evidence of lymph node metastasis?
A: Managing papillary thyroid microcarcinoma (PTMC), defined as papillary thyroid cancer measuring 1 cm or less, often requires individualized approaches. In patients with low-risk features, such as no extrathyroidal extension or lymph node involvement, and excellent surgical candidates, active surveillance may be a viable option. Active surveillance involves close monitoring with periodic ultrasound examinations and thyroid function tests. However, factors like patient preference, anxiety related to active surveillance, and specific tumor characteristics should also inform the decision-making process. Surgical resection (lobectomy or total thyroidectomy) remains the standard treatment for most PTMC patients. Consider implementing a shared decision-making approach to tailor management for individual patients with PTMC. Learn more about the latest ATA guidelines on the management of PTMC.
Papillary thyroid cancer diagnosis confirmed following fine needle aspiration biopsy revealing characteristic cytological features including nuclear grooves, intranuclear inclusions, and psammoma bodies. Patient presented with a palpable thyroid nodule, initially detected on physical exam. Ultrasound of the thyroid demonstrated a hypoechoic, solid nodule measuring 1.5 cm in the right lobe with irregular margins and microcalcifications, raising suspicion for malignancy. Thyroid function tests including TSH, free T4, and free T3 were within normal limits. No cervical lymphadenopathy was appreciated on physical exam or imaging. Differential diagnosis included follicular adenoma, Hürthle cell neoplasm, and other thyroid malignancies. Given the cytology results, the patient has been scheduled for total thyroidectomy and central neck dissection. Postoperative radioactive iodine therapy and thyroid hormone suppression therapy will be considered based on final pathology, including tumor size, extrathyroidal extension, and lymph node involvement. Molecular testing for BRAF mutation analysis will be performed on the surgical specimen to further inform prognosis and guide management decisions. Patient education provided regarding the diagnosis, treatment options, potential complications, and long-term follow-up including thyroglobulin monitoring and neck ultrasound surveillance. Referral to endocrinology for ongoing management and thyroid hormone replacement therapy. ICD-10 code C73.9 Papillary thyroid carcinoma, unspecified will be utilized for billing.